Duration of DAPT for Iliac Bare Metal Stents
For iliac bare metal stents, I recommend 1 month of dual antiplatelet therapy (aspirin plus clopidogrel), though direct evidence for peripheral arterial stents is limited and extrapolated from coronary guidelines.
Evidence Base and Rationale
The recommendation is primarily extrapolated from coronary artery guidelines, as no high-quality guidelines specifically address DAPT duration for peripheral arterial bare metal stents. The available evidence comes from:
Coronary BMS Guidelines (Applied by Extrapolation)
The 2016 ACC/AHA guidelines provide the strongest evidence for bare metal stents, recommending:
- Minimum 1 month of clopidogrel after BMS implantation in stable ischemic heart disease 1
- Daily aspirin 81 mg (range 75-100 mg) continued indefinitely 1
The 2007 ACC/AHA perioperative guidelines similarly recommend at least 1 month of thienopyridine therapy after bare-metal stent placement, noting that stent thrombosis is most common in the first 2 weeks and becomes exceedingly rare (less than 0.1%) after 4 weeks once endothelialization occurs 2, 3, 2.
Supporting Research Evidence
Research from coronary BMS populations demonstrates:
- A 2018 study showed that DAPT duration <2 months after BMS was as safe as prolonged DAPT ≥2 months for both acute MI and non-AMI patients (HR 0.97,95% CI 0.79-1.19) 4
- A 2015 randomized trial in BMS patients found no significant difference in stent thrombosis (0.5% vs 1.11%, p=0.24) or MACCE (4.04% vs 4.69%, p=0.72) when comparing 30 months versus 12 months of DAPT 5
Peripheral Arterial Practice Patterns
A 2016 German survey of 89 vascular centers revealed mean DAPT duration for iliac BMS was 1 month, though practice varied considerably 6. This real-world data suggests 1 month is the accepted standard among vascular specialists.
Practical Algorithm
Standard approach:
- Start DAPT immediately after iliac BMS placement: Aspirin 81 mg daily + Clopidogrel 75 mg daily
- Continue DAPT for 1 month minimum (ideally 4-6 weeks to ensure complete endothelialization)
- After 1 month: Discontinue clopidogrel, continue aspirin indefinitely
High-risk scenarios requiring longer DAPT (consider 3 months):
- Multiple overlapping stents
- Suboptimal stent deployment
- History of prior stent thrombosis
- Critical limb ischemia presentation
- Poor distal runoff
Early discontinuation considerations (2 weeks minimum):
- High bleeding risk (e.g., need for oral anticoagulation, recent major bleeding)
- Urgent surgery required
- Significant bleeding complications on DAPT
Critical Caveats
The major limitation is that all evidence is extrapolated from coronary circulation, where flow dynamics, vessel size, and thrombotic risk differ from iliac arteries. Peripheral arteries generally have:
- Lower flow velocities (potentially higher thrombotic risk)
- Larger vessel diameter (potentially lower thrombotic risk)
- Different plaque characteristics
If urgent surgery is needed within 1 month of stent placement, the risk of stopping DAPT must be weighed against surgical bleeding risk. Consider continuing aspirin perioperatively if possible 2.
The French Task Force consensus emphasizes that withdrawing antiplatelet therapy is a major risk factor for thrombosis for all stent types, particularly within the first 4-6 weeks 7.